Streetbeat News

ICCM

IceCure Medical Ltd

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.18

Mkt cap

63M

Volume

338K

High

1.19

P/E Ratio

-4.11

52-wk high

1.57

Low

1.12

Div yield

N/A

52-wk low

0.48

IceCure Medical Ltd. presented data on its ProSense® Cryoablation technology for low-risk breast cancer at the Radiological Society of North America's 2024 Annual Meeting. The FDA Advisory Panel has voted in favor of its benefit-risk profile, with a marketing authorization decision expected in Q1 2025.

Portfolio Pulse from

December 16, 2024 | 1:45 pm

IceCure Medical Ltd (NASDAQ: ICCM) held its Q3 2024 earnings conference call on November 26, 2024. Key participants included Michael Polyviou, Ronen Tsimerman, Tlalit Tel-Tzure, and Shay Levav. Analysts from Maxim Group, Brookline Capital Markets, and H.C. Wainwright participated in the call.

Portfolio Pulse from

November 26, 2024 | 7:00 pm

IceCure Medical Ltd. (ICCM) reported a Q3 loss of $0.08 per share, missing the Zacks Consensus Estimate of a $0.07 loss.

Portfolio Pulse from

November 26, 2024 | 4:00 pm

IceCure Medical Ltd. has received a Notice of Allowance from the Japan Patent Office for its next-generation multiprobe cryoablation technology, which facilitates the treatment of larger tumors.

Portfolio Pulse from

November 25, 2024 | 1:45 pm

IceCure Medical Ltd. (Nasdaq: ICCM) will release its Q3 2024 financial and operational results on November 26, 2024. The company specializes in cryoablation technology for tumor treatment.

Portfolio Pulse from

November 20, 2024 | 1:45 pm

IceCure Medical's ProSense® technology is being used in the PRECICE study for breast cryoablation, led by the European Institute of Oncology and sponsored by the Italian Ministry of Health. The study focuses on treating early-stage breast cancer in patients over 50, aiming to reduce surgical interventions.

Portfolio Pulse from

November 19, 2024 | 1:45 pm

The FDA Advisory Panel has voted in favor of IceCure Medical's ProSense® cryoablation technology for early-stage low-risk breast cancer, with a decision on marketing authorization expected in Q1 2025.

Portfolio Pulse from

November 08, 2024 | 12:15 pm

IceCure Medical shares rose following the announcement of significant public comments from key stakeholders before the FDA panel review for ProSens® cryoablation in early-stage low-risk breast cancer.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 2:36 pm

IceCure Medical announced that numerous public comments from key stakeholders have been posted ahead of the FDA Advisory Panel meeting on November 7, 2024, for the marketing authorization of its ProSense Cryoablation System for early-stage low-risk breast cancer.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:39 pm

IceCure Medical has received a Notice of Allowance from the U.S. Patent Office for its next-generation cryoablation system, which includes innovative technology for enhanced usability and cryogen integrity. The XSense system, already FDA-cleared, is set to address needs in the $1.67 billion global tumor ablation market.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.